Report Highlights

U.S. Pea Protein: Market Overview

The U.S. pea protein market differs from the global norm because demand is anchored in packaged food and sports nutrition rather than in commodity feed or Asian food processing. Domestic consumption is estimated at USD 412 million in 2024, roughly 40% of global pea protein value, making the United States the largest single national market. Roquette's Keokuk, Iowa plant and Puris's Minnesota operations provide rare domestic processing capacity, yet most raw yellow peas still arrive from Canada, the largest exporter, and Russia.

Unlike Europe, where pea protein is concentrated in dairy alternatives and meat extension, American buyers focus on protein-fortified beverages, plant-based snacks and performance powders. Pricing is benchmarked against whey concentrate and soy isolate, so pea protein must win on functionality, clean-label credentials and amino acid completeness rather than on cost. Procurement teams typically specify isolates above 80% protein with low sodium and minimal off-flavour, which narrows the qualifying supplier pool considerably.

Growth Drivers in U.S. Pea Protein

Consumer protein demand is the first driver, with American shoppers increasingly seeking high-protein labelling. FDA's 2016 Nutrition Facts rule, codified at 21 CFR 101.9, calculates protein %DV using PDCAAS, and pea protein isolate typically scores between 0.82 and 0.90, which keeps it competitive on label claims. Sports nutrition brands such as Orgain and Ripple Foods have expanded plant-protein product lines, and GLP-1 medication users are adopting high-protein, low-volume diets that favour dense protein sources.

Agricultural policy is the second driver. Dry pea production is concentrated in North Dakota and Montana, and federal crop insurance covering dry peas, alongside research funded through USDA's Pulse Crop Health Initiative and NIFA grants, supports stable pulse acreage. Third, the Dietary Guidelines for Americans 2020-2025 encourage varied plant protein sources, which supports the gradual shift of foodservice and institutional menus toward pea-based meat alternatives.

Market Restraints and Entry Barriers

The most consequential barrier is the GRAS pathway. Many pea protein ingredients rely on self-affirmed GRAS status under 21 CFR 170.36, but HHS has directed FDA to explore ending self-affirmation, which would require formal notification with review timelines of roughly 180 days and expose unnotified suppliers to rejection. Tariff exposure compounds this, as Canadian-origin peas must satisfy USMCA rules of origin while Chinese-origin pea protein falls under HTS 3504.00 and carries Section 301 duties.

Incumbent advantage is the second barrier. Roquette and Puris hold domestic isolate capacity and long-term contracts with major sports nutrition and meat-alternative brands, while Chinese exporters such as Yantai Shuangta Food and Shandong Jianyuan Biotechnology compete aggressively on price. Functional performance is the third barrier, since pea isolates require enzymatic or pH treatment to suppress beany off-notes, adding reformulation cost and qualification time for new entrants.

Market Opportunities in the U.S.

Textured pea protein for meat analogues is the nearest-term opportunity. Plant-based meat sales in U.S. retail have contracted, but foodservice blends and hybrid meat products containing 10-30% pea protein are growing, with an addressable pool we estimate at USD 120 million in 2025. Sports and clinical nutrition offers a second opening, as performance powders and ready-to-drink shakes built on pea isolate represent an estimated USD 150 million segment where brands seek non-dairy, non-soy formulations.

Co-location in the Upper Midwest offers a third opening. Toll-processing and co-manufacturing capacity near Keokuk and in Minnesota remains underused by mid-sized brands, allowing entrants to avoid a greenfield isolate plant estimated at USD 50-80 million. Clean-label dairy alternatives, where pea protein blends with oat and almond bases, present a further pool of roughly USD 90 million, favouring suppliers that deliver non-GMO and organic-certified isolates.

Market at a Glance

Leading Market Participants

• Roquette Frères
• Cosucra Groupe Warcoing
• Puris
• Ingredion
• Axiom Foods
• Burcon NutraScience
• Cargill
• Archer Daniels Midland
• Shandong Jianyuan Biotechnology
• Yantai Shuangta Food

Regulatory and Policy Environment

FDA regulates pea protein as a food ingredient under the Federal Food, Drug, and Cosmetic Act, with GRAS determinations under 21 CFR Part 170 and labelling requirements under 21 CFR 101.9. Notified GRAS submissions typically receive an FDA response within about 180 days, and a voluntary pre-market consultation can extend that timeline. Importers must also comply with the Foreign Supplier Verification Program under 21 CFR Part 1 Subpart L before shipments enter the United States.

USDA's Pulse Crop Health Initiative and NIFA research programmes under the Farm Bill fund pulse agronomy, while federal crop insurance administered through the Risk Management Agency covers dry pea production. Trade policy is the sharper lever, as Section 301 duties on Chinese goods and USMCA rules of origin govern landed costs, and U.S. Customs and Border Protection enforces classification through HTS audits. Buyers should budget 60 to 90 days for FSVP documentation based on typical supplier onboarding.

Long-Term Outlook for U.S. Pea Protein

By 2032 the U.S. pea protein market is projected to reach USD 735 million, growing at a 7.5% CAGR from USD 412 million in 2024. Growth will be led by textured pea protein in hybrid meat products and performance nutrition, while dairy alternatives grow more slowly as oat competition intensifies. Domestic processing capacity will expand in the Upper Midwest, reducing reliance on Canadian-origin isolate, though Roquette and Puris will retain the largest share of supply.

Regulatory tightening will reshape the supplier base. Mandatory GRAS notification would eliminate uncertified self-affirmed suppliers and favour integrated players with dossier resources. Entrants that secure FDA notifications early will capture the premium contracts that come with them, and we expect three to four suppliers to control most domestic isolate volume by 2032.